Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
This development was enabled by a constantly evolving understanding of the interplay between the different ADC components and their relationship with disease biology. A striking example is the human epidermal growth factor receptor 2 (HER2) space, 4 where Kadcyla (ado?trastuzumab Tubulis’ second technology platform is called Tub?tag
Let's personalize your content